Controlled release effervescent buccal discs of buspirone hydrochloride:<i>in vitro</i>and<i>in vivo</i>evaluation studies

Jaipal, A.; Pandey, Murali Monohar; Sy, Charde; Sadhu, Naveen; Srinivas, Akhila; Rg, Prasad

doi:10.3109/10717544.2014.917388

Cited by 26 publications

(20 citation statements)

References 53 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mucoadhesive strength of tablets was determined by using a texture analyzer (Middleboro, MA, USA). 20 , 26 Fresh buccal mucosa from the sheep obtained from local slaughterhouse was used as a model membrane. Samples were prepared by separating the underlying adipose tissue, and the obtained mucosal membrane was cut into 2×2 cm pieces.…”

Section: Methodsmentioning

confidence: 99%

Risperidone mucoadhesive buccal tablets: formulation design, optimization and evaluation

Çelik

2017

DDDT

View full text Add to dashboard Cite

The aim of this study was to design and optimize risperidone (RIS) mucoadhesive buccal tablets for systemic delivery as an alternative route. Direct compression method was used for the preparation of buccal tablets, and screening studies were conducted with different polymers to determine their effects on tablet characteristics. Carbopol® (CP) and sodium alginate (SA) were selected as two polymer types for further optimization studies by applying response surface methodology. Tablet hardness (TH), ex vivo residence time (RT), and peak detachment force (DF) from buccal mucosa were selected as three important responses. Physicochemical compatibility of formulation excipients and RIS was evaluated by using Fourier transform infrared (FT-IR) spectroscopy and differential scanning calorimetry (DSC) analysis. In vitro drug release profiles and release kinetics were investigated; swelling index and matrix erosion studies were conducted. Optimum formulation consisted of 16.4% CP and 20.3% SA, which provided 7.67±0.29 hour ex vivo RT, 45.52±4.85 N TH, and 2.12±0.17 N DF. FT-IR spectroscopy and DSC analysis revealed that there was no chemical interaction present between tablet ingredients. Cumulative RIS release of >90% was achieved after 8 hours of in vitro dissolution studies, which was supported by swelling and matrix erosion analysis. Mechanism of RIS release was fitted best to zero-order model, while release exponent (n) value of 0.77 demonstrated an anomalous (non-Fickian) release, indicating combined erosion and swelling mechanism. The results suggested that optimized buccal tablets of RIS would be a promising and alternative delivery system for the treatment of schizophrenia.

show abstract

Section: Methodsmentioning

confidence: 99%

Risperidone mucoadhesive buccal tablets: formulation design, optimization and evaluation

Çelik

2017

DDDT

View full text Add to dashboard Cite

show abstract

“…Jaipal et al showed that the carbon dioxide released from buccal effervescent discs upon contact with saliva acts as a permeation enhancer (compared to noneffervescent discs) (61). Although this is an attractive alternative for pediatric patients due to the increased bioavailability effect, further investigations are required to assess the safety of this dosage form.…”

Section: Effervescent Buccal Discsmentioning

confidence: 98%

Buccal Dosage Forms: General Considerations for Pediatric Patients

2016

View full text Add to dashboard Cite

The development of an appropriate dosage form for pediatric patients needs to take into account several aspects, since adult drug biodistribution differs from that of pediatrics. In recent years, buccal administration has become an attractive route, having different dosage forms under development including tablets, lozenges, films, and solutions among others. Furthermore, the buccal epithelium can allow quick access to systemic circulation, which could be used for a rapid onset of action. For pediatric patients, dosage forms to be placed in the oral cavity have higher requirements for palatability to increase acceptance and therapy compliance. Therefore, an understanding of the excipients required and their functions and properties needs to be particularly addressed. This review is focused on the differences and requirements relevant to buccal administration for pediatric patients (compared to adults) and how novel dosage forms can be less invasive and more acceptable alternatives.

show abstract

“…Effervescent tablets (ETs) can quickly disintegrate because of the gas-generating reaction of an acidic agent (e.g., citric acid) and an alkaline agent (e.g., sodium bicarbonate) when coming into contact with water, therefore accelerating the release and improving the bioavailability of the included drugs. 1,2 However, certain drawbacks (e.g., frequent sticking, high hygroscopicity, and low hardness) of the ETs limit their practical production and applications. In particular, sticking can frequently occur in the tableting process due to the ease with which the acidic agent adheres onto the punch tips of the tablets during compaction.…”

Section: Introductionmentioning

confidence: 99%

Improvements in sticking, hygroscopicity, and compactibility of effervescent systems by fluid-bed coating

Zheng

Yang

et al. 2019

RSC Adv.

View full text Add to dashboard Cite

show abstract

Controlled release effervescent buccal discs of buspirone hydrochloride:in vitroandin vivoevaluation studies

Cited by 26 publications

References 53 publications

Risperidone mucoadhesive buccal tablets: formulation design, optimization and evaluation

Risperidone mucoadhesive buccal tablets: formulation design, optimization and evaluation

Buccal Dosage Forms: General Considerations for Pediatric Patients

Improvements in sticking, hygroscopicity, and compactibility of effervescent systems by fluid-bed coating

Contact Info

Product

Resources

About